Publications by authors named "N Maisey"
Purpose: Open-label phase II study (RELATIVITY-060) to investigate the efficacy and safety of first-line nivolumab, a PD-1-blocking antibody, plus relatlimab, a lymphocyte-activation gene 3 (LAG-3)-blocking antibody, plus chemotherapy in patients with previously untreated advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC).
Methods: Patients with unresectable, locally advanced or metastatic GC/GEJC were randomly assigned 1:1 to nivolumab + relatlimab (fixed-dose combination) + chemotherapy or nivolumab + chemotherapy. The primary end point was objective response rate (ORR; per RECIST v1.
Article Synopsis
- This study investigates the impact of pathological lymph node (LN) regression after neoadjuvant chemotherapy on survival rates in patients with esophageal adenocarcinoma, addressing a gap in existing research and defining LN response classifications.
- Conducted across five UK centers, the study analyzed 17,930 LNs from 763 patients, assigning scores based on the extent of residual tumor found in the nodes after treatment, with survival outcomes assessed using advanced statistical methods.
- Results showed that patients with complete or partial LN response had significantly lower mortality rates compared to those with poor or no LN response, highlighting LN regression as a vital prognostic factor that should be considered alongside traditional staging methods.
Introduction: Better predictive markers are needed to deliver individualized care for patients with primary esophagogastric cancer. This exploratory study aimed to assess whether pre-treatment imaging parameters from dynamic contrast-enhanced MRI and F-fluorodeoxyglucose (F-FDG) PET/CT are associated with response to neoadjuvant therapy or outcome.
Materials And Methods: Following ethical approval and informed consent, prospective participants underwent dynamic contrast-enhanced MRI and F-FDG PET/CT prior to neoadjuvant chemotherapy/chemoradiotherapy ± surgery.
Article Synopsis
- - The study evaluated the effectiveness of various staging methods (CT, EUS, and FDG-PET/CT) for diagnosing high-grade dysplasia or early adenocarcinoma in esophageal cancer patients treated between 2000 and 2019.
- - Results showed low accuracy rates: EMR (CT 40.1%, EUS 29.6%, FDG-PET/CT 11%) and esophagectomy (CT 43.3%, EUS 59.7%, FDG-PET/CT 29.6%), with significant misdiagnoses that could have affected treatment decisions.
- - Overall, the alternative investigations only altered clinical management in 3.2% of early cancer cases